

A microsimulation model to estimate the quality of life and cost of inherited retinal diseases (IRDMOD)

Presenter: Joshua Kraindler, Centre for Economic Impacts of Genomic Medicine, Macquarie University. Authors: Deborah Schofield, Joshua Kraindler, Owen Tan, Rupendra Shrestha, Diana Jelovic, Sarah West, Natalie Hart, Alan Ma, John Grigg, Robyn V Jamieson



IRDMOD





- 1. What are Inherited Retinal Diseases (IRDs)
- 2. Primary data collection to estimate costs and quality of life (QoL)
- 3. IRDMOD
- 4. Next steps





Inherited retinal diseases (IRDs)

- IRDs are a group of rare genetic diseases, estimated to affect between 1 in 1,000 and 1 in 2,000 people (Liew et al 2014, Hannay et al 2020).
- IRDs comprise a group of vision disorders which cause retinal dysfunction and degeneration leading to progressive vision loss and blindness (Duncan et e 2018)
- They are now the leading cause of legal blindness in working age adults (Viriato et al 2020).
- They often have early onset of disease and symptoms, leading to a substantial disease burden on both patients and their carers/families (Grigg et al 2020).
- Until recently, there were no treatment options for IRDs
- From around 2019, regulatory bodies, governments and other funders began to approve and fund use of Luxturna, a gene therapy for people with *RPE65 retinopathy*, a rare form of IRD
- So far, results of this gene therapy have been very promising
- However, there is very limited data on the impact of IRDs



IRDs continued

- In Australia, when the Medical Services Advisory Committee (MSAC) recommended funding it, they acknowledged a lack of utility data and any non-health care related costs
- In the UK, the list price in 2019 was over £600,000 per patient, with the negotiated price for the NHS kept confidential
- There are many other gene therapies for IRDs in trials
- As a result, data is needed to evaluate the cost effectiveness of any gene therapies, as well as access to genetic testing and genome sequencing
- We worked with a team of health economists, geneticists, genetic counsellors and ophthalmologists to collect primary data on IRDs and develop a model to allow decision makers to understand the impact of the disease and the potential benefits of any interventions





Primary data collection


- Tailored questionnaire the Economic and Psychosocial Impact of Caring for Families Affected by Visual Impairment
- All patients with a clinical diagnoses who attended a genetic of ophthalmic consultation at Children's hospital in Westmead or Save Sight Institute Sydney were invited
- Interviews are performed by research assistants and genetic counsellors, often up to 4 hours in length
- Collects data across every domain, health, social, quality of life, genetics, service use
- Patients under 18 are interviewed by proxy
- Carers and patients are interviewed

Administrative data

• For health data, data linkage is used to obtain health service utilisation and costs



IRDMOD structure



OFFICE | FACULTY | DEPARTMENT

MACQUARIE BUSINESS SCHOOL


IRDMOD QUALITY OF LIFE ANALYSIS

- In health economic analysis, health utility values are required for measuring • quality of life
- This requires a validated instrument •
- In EPIC-Vision we collected the Assessment of Quality of Life 8 Dimension • (AQoL-8D) 1.000 0.941

0.000 Independent Relationships Self-worth Pain Senses Mental Coping Happiness Living Health IRD patients Population Norms Population norm values for dimensions are scores which are unweighted by utilities. Total AQoL-8D refers to

AQoL-8D utility value. One sample t-tests were significant at the 0.05 level for all dimensions and total utility values.

AQoL-8D = Assessment of Quality-of-Life 8D







IRDMOD COSTS

- We model the lifetime costs of IRDs using a combination of data collected from EPIC-Vision, linked health data and counterfactual income and tax modelling
- This is done by estimating average annual costs in each age group, multiplied by time in age group, summed over average life expectancy in Australia
- Costs are estimated for each individual with IRD and their carer and spouse
- Microsimulation modelling allows us to be able to change inputs for each individual (if examining an intervention) and their carer/spouse
- Each cost is assigned to a payer:
 - Government state/federal
 - Patient
 - Carer
 - Other



IRDMOD HEALTH AND SOCIETAL COSTS

- Societal costs are estimated from data collected in EPIC-Vision
- This includes social service use, income support payments, use of the National Disability Insurance Scheme and income losses
- Where possible, costs are taken from published sources, such as current income support levels
- Health costs are a combination of self-reported data and linked
 administrative health data in Australia

Counterfactual modelling – patients, carers and spouses

- We collect data on patient, carer and spouse incomes
- Using the static income model (STINMOD), we match individuals to STINMOD based on age, gender, state of residence and education (IRDs in our cohort did not seem to impact education)
- Income loss is taken as the difference between their current income and the average of the simulations (1,000) from STINMOD
- Similar is performed for tax, with an added step of tax imputation of EPIC-Vision cohort as they did not report tax paid



IRDMOD Lifetime cost

						F	Patient co	sts					Carer	and spou	se costs	Total	costs
N	Age group	Commonwealth government				State government			Private			0.1	Commonwealth government		Private	Total cost	Total cost
		Health System	Social	NDIS	Tax receipts	Health system	Social	NDIS	Health	OOP expenses other	Lost income	Other	Social	Tax receipts	Carer and	per patient	per household
6	0 to 5	15,859	1,335	7,948	-	14,482	4,004	5,755	3,655	3,266	-	79	9,356	4,587	16,210	385,906	416,372
17	6 to 18	1,675	7,955	7,844	282	272	4,314	5,680	1,198	2,646	1,263	56	13,721	11,122	32,408	1,350,313	1,456,916
21	19 to 29	874	11,430	4,106	599	158	-	2,973	894	544	4,286	45	2,348	3,889	11,796	1,733,090	1,869,913
9	30 to 39	9,767	10,889	7,895	9,015	9,020	-	5,717	825	343	31,163	105	751	200	1,112	2,485,243	2,681,447
15	40 to 49	2,003	10,999	5,365	11,535	933	-	3,885	1,968	416	29,009	221	-	577	1,185	3,058,440	3,299,896
14	50 to 59	2,693	15,653	3,910	17,198	1,000	-	2,831	1,533	793	44,494	1,181	-	5,250	14,841	4,020,110	4,337,487
6	60 to 69	3,382	16,683	7,612	8,373	1,079	333	5,512	2,108	1,210	29,028	1,339	563	4,043	15,862	4,826,609	5,207,657
6	70 - 84	2,522	17,025	-	333	615	-	-	912	1,137	2,853	630	-	2,074	12,518	5,159,644	5,566,985



IRDMOD WHAT IS THE COST OF A RARE DISEASE?

Commonwealth government	
Health	324,429
Social spending excl National	
Disability Insurance Scheme	1,016,419
(NDIS) - patient	
NDIS	434,688
Social spending - carer	264,113
Tax receipts - patient	476,140
Tax receipts - carer/spouse	340,031
Total	2,855,820
State Government	
Health	206,614
Social spending - patient	79,439
NDIS	314,774
Total	600,828
Individual/household	
Health	120,789
Other including	100,254
aids/modifications	100,234
Lost income - patient	1,440,453
Lost income - spouse/carer	1,137,364
Total	2,798,860
Private health insurance	20 002
spending**	38,893
Total cost (after adjustment)*	5,159,644

Annual costs by visual acuity	\$
Better than or equal to 6/60 (N=45)	41,357
Worse than 6/60 (N=49)	83,910
Annual costs by gender	
Female (N=55)	54,527
Male (N=39)	76,067



IRDMOD WHERE TO NEXT?

- IRMOD has been designed to be adaptable
 - The outputs shown in this presentation were for all IRDs
 - The model can be estimated on sub-groups of this analysis
- Estimating interventions?
 - Determined by the impact of the intervention
 - For example, as the model is a lifetime cost model by age group, it can be used to estimate changes in costs and benefits at different ages or disease progression
- Societal costs
 - The outputs on whole IRD costs as well as QoL impacts shown the significant disease burden of IRDs
 - There are substantial QoL impacts
 - Most costs are societal, these must be considered in evaluations



References

- 1. Duncan JL, Pierce EA, Laster AM, Daiger SP, Birch DG, Ash JD, et al. Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps. Transl Vis Sci Technol. 2018;7(4):6.
- 2. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open. 2014;4(2):e004015.
- 3. Hanany M, Rivolta C, Sharon D. Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases. Proc Natl Acad Sci U S A. 2020;117(5):2710-6.
- 4. Viriato D, Bennett N, Sidhu R, Hancock E, Lomax H, Trueman D, et al. An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK. Adv Ther. 2020;37(3):1233-47.
- 5. Grigg J, Jamieson R, Chen F, et al. Guidelines for the assessment and management of patients with inherited retinal diseases (IRD). The Royal Australia and New Zealand College of Ophthalmologists. 2020. <u>https://ranzco.edu/policies_and_guideli/guidelines-for-the-assessment-and-management-of-patients-with-inherited-retinal-degenerations-ird/</u>.